40th week of 2011 patent applcation highlights part 47 |
Patent application number | Title | Published |
20110243948 | Monoclonal Antibodies Against ANGPTL3 - Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided. | 2011-10-06 |
20110243949 | COMPOSITION FOR PRODUCING ANTI-AMYLOID BETA PEPTIDE ANTIBODIES WITH D-PEPTIDES - The present invention relates to a composition comprising D-peptides or antibodies for use as a therapeutic and/or for disease prevention, wherein
| 2011-10-06 |
20110243950 | MSP2 ANTIGENIC PEPTIDES AND THEIR USE - This invention relates generally to the field of | 2011-10-06 |
20110243951 | IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS AND IMMUNOTOXINS - It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other things, to treat disease caused by asthma and chronic inflammation such as for example inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells. | 2011-10-06 |
20110243952 | COMPOUND AND METHOD FOR REGULATING PLASMINOGEN ACTIVATION AND CELL MIGRATION - The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof. | 2011-10-06 |
20110243953 | NEUTRALIZING ANTIBODIES AGAINST GDF-8 AND USES THEREFOR - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism. | 2011-10-06 |
20110243954 | PEPTIDES CAPABLE OF BINDING TO SERUM PROTEINS AND COMPOUNDS, CONSTRUCTS AND POLYPEPTIDES COMPRISING THE SAME - Provided are pharmaceutical compositions, preparations or formulations including a compounds or constructs that include at least one amino acid sequence that is directed against serum albumin and at least one therapeutic moiety. The pharmaceutical compositions, preparations or formulations are preparations or formulations that are suitable for and/or intended for, e.g., pulmonary administration. Methods for use of the pharmaceutical compositions, preparations or formulations also are provided. | 2011-10-06 |
20110243955 | ANTIBODY AND USES THEREOF - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis | 2011-10-06 |
20110243956 | METHODS OF DIAGNOSING AND TREATING COMPLICATIONS OF PREGNANCY - Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity. | 2011-10-06 |
20110243957 | MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION - The subject invention concerns methods for preventing and/or treating neurodegenerative conditions associated with Abeta peptide accumulation in neural tissue in a human or animal. The subject invention also concerns methods for preventing or treating Alzheimer's disease-like neuropathology in a person or animal having trisomy 21 (Down's syndrome). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of a compound that inhibits function or activity of a Raf protein to a person or animal in need of treatment. In a specific embodiment, the Raf inhibitor is Sorafenib (NEXAVAR). Neurodegenerative conditions contemplated within the scope of the present invention include, for example, Alzheimer's disease and Parkinson's disease. The subject invention also concerns methods for preventing or inhibiting neuronal cell death and/or improving cell viability. | 2011-10-06 |
20110243958 | ANTIMICROBIAL AGENTS THAT TARGET BACTERIAL VKOR - Aspects of the invention relate to a method for inhibiting the growth of a microbe that expresses bacterial vitamin K epoxide reductase (bVKOR). The method involves contacting the bacterial cell with an effective amount of an agent that inhibits bVKOR. Agents include a drug, ligand or portion thereof, protein, polypeptide, small organic molecule, antisense nucleic acid, RNAi, or antibody. Examples of useful agents are a phenylpropanoid, a modified phenylpropanoid, a coumarin or modified coumarin. A particularly useful agents is warfarin or a variant thereof or ferulenol or a variant thereof. The microbe is any microbe carrying a bVKOR gene, such as | 2011-10-06 |
20110243959 | MODULATING NEURONAL PLASTICITY AND TREATMENT OF NEURONAL LOSS BY MODULATIONG WNT7A OR WNT7B MODULATION - The present invention relates to a method of treating or preventing a disease characterized by a loss or imbalance of neuronal connections, wherein said disease characterized by a loss or imbalance of neuronal connections is selected from a group of diseases consisting of age-related loss of neuronal performance and/or connections, psychiatric disorders, neurodegenerative diseases characterized by loss of neuronal connections, learning deficiency, and senile dementia, of modulating neuronal activity and/or neuronal plasticity, of optimizing repair after brain injury, to modulate learning, and/or to modulate cognitive capabilities, in a subject and/or, of preventing loss of neuronal connections and/or to increase neuronal connections in said subject, by modulating Wnt-signaling, which method is characterized by the fact that the subject is in puberty or post-puberty, wherein puberty or post-puberty means that the neuronal circuits of said subject have already undergone developmental synapse elimination and critical periods which take place prior to puberty. | 2011-10-06 |
20110243960 | METHODS AND COMPOSITIONS FOR TREATING P. ACNES - The disclosure provides an antigenic composition useful for immunization against | 2011-10-06 |
20110243961 | METHODS FOR TREATING BONE CANCER BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST ANTIBODY - The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF. | 2011-10-06 |
20110243962 | THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES - The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6. | 2011-10-06 |
20110243963 | ANTIBODIES TO LRP6 - Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing. | 2011-10-06 |
20110243964 | TREATMENT OF ORTHOPEDIC CONDITIONS - Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorders, diseases, or conditions, and improving recoveries and outcomes of orthopedic procedures or surgeries. | 2011-10-06 |
20110243965 | ANTIBODIES AGAINST DOMAINS OF LAMININ-332 - Antibodies against various domains of laminin-332 are discussed herein. The antibodies reduce the adhesion and matrix binding properties of laminin-332, inhibiting tumor growth and metastasis in vivo. Pharmaceutical compositions and methods of using the antibodies for diagnostic, prophylactic, and/or therapeutic purposes are disclosed. | 2011-10-06 |
20110243966 | SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO - The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject. | 2011-10-06 |
20110243967 | MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES - Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. | 2011-10-06 |
20110243968 | THERAPEUTIC APPLICATIONS OF P53 ISOFORMS IN REGENERATIVE MEDICINE, AGING AND CANCER - The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation. | 2011-10-06 |
20110243969 | PRODUCTION OF SQUALENE FROM HYPER-PRODUCING YEASTS - A method for preparing purified yeast is disclosed, where the squalene source is a yeast that hyper-produces squalene. The squalene is useful for pharmaceutical purposes. For instance, it can be used to prepare an oil-in-water emulsion, and the emulsion is particularly suitable for use as an immunological adjuvant. | 2011-10-06 |
20110243970 | COMPOSITION FOR INHIBITION OF TRANSPLANT REJECTION CONTAINING THE CORDYCEPS MYCELLIA EXTRACT AS AN ACTIVE INGREDIENT - Disclosed is a composition for the inhibition of transplant rejection and the treatment of skin diseases, comprising a cordyceps mycellia extract as an active ingredient. The cordyceps mycellia extract significantly suppresses the production of antibodies to transplants without side effects, such as weight change. Based on natural material, the composition is non-toxic and harmless to the human body and thus can be used as an immunosuppressant for organ transplantation. Also, it stops oozing from sores and is useful in the treatment of skin diseases, including atopy, allergic reactions, decubitus ulcers, pemphigus and smallpox. | 2011-10-06 |
20110243971 | Vaccines - The invention relates to a vaccine composition comprising an antigen, an immunologically active saponin fraction and a sterol. | 2011-10-06 |
20110243972 | PROSTATE STEM CELL ANTIGEN VACCINES AND USES THEREOF - This invention relates to the identification of prostate stem cell antigen (PSCA) as a target of clinically relevant antitumor immune responses. The invention provides vaccines comprising PSCA, or fragments thereof, which are useful in inducing antitumor immune responses, including PSCA specific CD8+ T cell responses. Methods of using the compositions to treat cancer are also provided. The invention further provides methods of identifying compounds useful in antitumor vaccines and methods of assessing the responses of patients to cancer immunotherapy. | 2011-10-06 |
20110243973 | HIG2 AND URLC10 EPITOPE PEPTIDE AND VACCINES CONTAINING THE SAME - The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents. | 2011-10-06 |
20110243974 | NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND TUMOR ANTIGEN PEPTIDES THEREOF - A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided. | 2011-10-06 |
20110243975 | TRANSFORMED SOYBEAN PLANT WHICH ACCUMULATES VACCINE, AND USE THEREOF - A transformed soybean plant having a gene encoding a modified seed storage protein introduced therein, obtained by inserting a gene encoding an Alzheimer's disease vaccine to a variable region(s) of a gene encoding a wild-type seed storage protein, is produced, and said vaccine is produced and accumulated in the seeds thereof. | 2011-10-06 |
20110243976 | COMPOSITIONS COMPRISING PNEUMOCOCCAL ANTIGENS - Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens. | 2011-10-06 |
20110243977 | SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES - β-hemolytic streptococci polynucleotides, polypeptides, particularly | 2011-10-06 |
20110243978 | ENTEROCOCCUS ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2011-10-06 |
20110243979 | Method of Transcutaneous Immunization Using Antigen - Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is preferred. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigen and adjuvant. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof. Systemic and/or regional immunity may be induced; immune responses that result in prophylaxis and/or therapeutic treatments are preferred. Antigen and adjuvant activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens and adjuvants which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a liquid formulation, patches or other medical devices may be used to deliver antigen for immunization. | 2011-10-06 |
20110243980 | METHODS AND SYSTEMS FOR O-GLYCOSYLATING PROTEINS - Described herein are methods and systems for O-glycosylating proteins in vivo or in vitro in any prokaryotic organism. In these methods and systems, DNA comprising a gene that produces a PglL-like oligosaccharyltransferase and DNA comprising a gene that produces a protein to be O-glycosylated are used. The PglL-like oligosaccharyltransferase facilitates the covalent attachment of the glycan to the protein to produce the O-glycosylated protein. The methods and systems described herein provide an approach for the design and production of new vaccines and therapeutic agents for the treatment of various diseases. | 2011-10-06 |
20110243981 | THERAPEUTIC MYELIN SHEATH DERIVED ANTAGONIST PEPTIDE CONJUGATES - A first aspect of the invention relates to a conjugate comprising: (i) mannan; and (ii) at least one epitope comprising a peptide fragment of a protein selected from myelin basic protein (MBP), myelin oligodentrocyte glycoprotein (MOG) and proteolipid protein (PLP), said peptide fragment being in linear or cyclic form; wherein said epitope is linked to mannan via a [(LyS-GIy)n] bridge, where n is an integer from 1 to 10. Further aspects of the invention relate to pharmaceutical compositions comprising said conjugates, and their use in the preparation of a medicament for treating an immune disorder. | 2011-10-06 |
20110243982 | Chimeric MSP-Based Malaria Vaccine - The invention provides an immunogenic composition comprising MSP-8 linked to an antigen. Methods of using the composition to induce an immune response in an animal are also provided. | 2011-10-06 |
20110243983 | COSMETIC USE OF SKIN CELL AUTOPHAGY ACTIVATORS - The object of the invention is the use in a cosmetic composition of an effective amount of at least one cutaneous cell autophagy activator as a cosmetic active ingredient. The invention also relates to cosmetic compositions that include at least one cutaneous cell autophagy activator as a cosmetic active ingredient | 2011-10-06 |
20110243984 | COMPOSITION FOR TREATMENT OF DIABETES MELLITUS AND A PREPARATION AND AN USE THEREOF - The present invention relates to a composition for treating diabetes and a preparation method thereof as well as use thereof. The present invention provides a composition for treating the diabetes, comprising the following active components based on the parts by weight: 10-100 parts of Pumpkin powder; 6-200 parts of spirulina; and 2-90 parts of Lychee Seed. The invention further provides the preparation method of the composition and the use of the medicament for treating the diabetes. By taking the composition, the blood sugar concentration of the diabetics can be effectively controlled, the complicating diseases of the diabetics can be avoided, and the health of the diabetics can be protected. | 2011-10-06 |
20110243985 | SELF-ADHESIVE MATRIX SYSTEM COMPRISING A STYRENE BLOCK COPOLYMER - Disclosed is a self-adhesive matrix system comprising a styrene-ethylene/butylene-styrene (SEBS) copolymer in an oil/ethyl acetate mixture, a hydrogenated resin and a pharmaceutical or cosmetic active ingredient. | 2011-10-06 |
20110243986 | POLYNUCLEOTIDES ALLOWING THE EXPRESSION AND SECRETION OF RECOMBINANT PSEUDO-VIRUS CONTAINING FOREIGN EPITOPES, THEIR PRODUCTION, AND USE - This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then to viral clearance. The vector of the invention, by expression of epitopes derived from common pathogens, by-passes existing tolerance of virus specific T cell responses. The vector will only replicate in virus infected cells. | 2011-10-06 |
20110243987 | INFLUENZA VACCINE - The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent. | 2011-10-06 |
20110243988 | Methods and Compositions for Stabilization of a Virus Vaccine - This invention provides compositions and methods for stabilizing a live attenuated virus in dried formulations. In particular, compositions and methods of preparing a dried vaccine are provided that stabilize the viability of live vaccines such as measles and adenovirus at room temperature. | 2011-10-06 |
20110243989 | IDNA VACCINES AND METHODS FOR USING THE SAME - Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus. | 2011-10-06 |
20110243990 | Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias - The invention relates to vaccines for treating prostate inflammation and benign prostate hyperplasias (stages I and II) comprising | 2011-10-06 |
20110243991 | PROCESS FOR PRODUCTION OF VACCINES - The invention relates to a process for the production of a vaccine against bacterial pathogens which produce an AB toxin, like | 2011-10-06 |
20110243992 | METHODS OF ENHANCING THE IMMUNOGENICITY OF MYCOBACTERIA AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUBERCULOSIS, AND FIBROSING LUNG DISEASES - Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity. | 2011-10-06 |
20110243993 | Method for diagnosing and creating immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments - A method is provided for diagnosis and induction of immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments, based on knowledge of the role that keratinocytes play in these ailments and is of importance for several conditions, including but not limited to allergic contact dermatitis (ACD), drug hypersensitivity reactions (DHRs) and autoimmune diseases. | 2011-10-06 |
20110243994 | STABILIZED PHARMACEUTICAL COMPOSITION, LIQUID PREPARATION OF STABILIZED PHARMACEUTICAL COMPOSITION, FILM-FORM PREPARATION, AND METHOD FOR PRODUCING FILM-FORM PREPARATION - The present invention provides a stabilized pharmaceutical composition that enables the production of a preparation for desensitization therapy useful as an agent for the prevention or treatment of allergic diseases such as pollen hypersensitivity, has outstanding allergen protein stability, and is useful for storage and transfer. | 2011-10-06 |
20110243995 | Method for Rational Mutagenesis of Alpha/Beta T-Cell Receptors and Correspondingly Mutated MDM2-Protein Specific Alpha/Beta T-Cell Receptors - The invention relates to the rational mutagenesis of polypeptides of α/β T-cell receptors that mediate an oncogen-specific T-cell response, nucleic acids encoding these and their use in the therapy, diagnosis and/or prevention of cancerous diseases. The invention further relates to a T-cell response-mediating MDM2-protein-specific α/β T-cell receptor, which has been rationally mutated by means of the method according to the present invention, and the uses thereof. | 2011-10-06 |
20110243996 | Spray freeze dry of compositions for intranasal administration - This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration. | 2011-10-06 |
20110243997 | FILM-FORM PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a film-form preparation having a rapid dissolution profile in the mouth and sufficient film strength, and also having excellent appearance and feel. More specifically, the present invention provides a film-form preparation including: a water-soluble and a polar organic solvent-soluble edible polymer; and polar organic solvent-insoluble drug particles. | 2011-10-06 |
20110243998 | PATCH PREPARATION AND PRODUCTION METHOD THEREOF - The invention provides a patch preparation containing (a) a support and (b) an adhesive layer containing a drug on the surface of the support, wherein a crystal of the drug is formed in the adhesive layer immediately after application of a physical stimulation to the adhesive layer, while a crystal of the drug is formed during preservation after the physical stimulation. The patch preparation which does not require an increase in the area and thickness of an adhesive layer, achieves a sufficiently high skin permeation amount of the drug, shows good adhesiveness to skin, and permits a long-term adhesion to skin. The invention also provides a method of producing the patch preparation. | 2011-10-06 |
20110243999 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS - The invention provides methods and compositions for the delivery of lipophilic drugs that are useful for the treatment of various ophthalmological diseases, disorders, and pathologies, including the treatment of age-related macular degeneration, diabetic retinopathy, diabetic macular edema, cancer, and glaucoma. | 2011-10-06 |
20110244000 | ANTIMICROBIAL FILM LAMINATE ASSEMBLIES AND METHODS OF USING AND MANUFACTURING THE SAME - An antimicrobial film laminate assembly is disclosed. The assembly includes an antimicrobial film laminate having a first surface at least partially coated with an adhesive and an opposing second surface, the antimicrobial film laminate includes at least one antimicrobial compound, and a unitary backing positioned upon the first surface of the antimicrobial film laminate. | 2011-10-06 |
20110244001 | System and method for the release of nitric oxide using nanoscale media - A composite material containing polymeric nanofibers, themselves containing NO-donor molecules, imbibed with an elastomer matrix is permeable to both water and gas so that dissociation reactions in the presence of water releases NO gas in a sustained manner. The NO-donor nanofibers may be formed by synthesizing acceptable NO-donor molecules, blending such molecules in solution with PVP, PCL or PVAc, electrospinning the blend at relatively high voltage for form fiber mats, applying PDMS rubber to the fiber mat and crosslinking it. The resulting NO-releasing electrospun fiber composite may be used in medical devices such as catheters, stents, or vascular grafts, with the purpose of releasing nitric oxide within a controlled rate and for a sustained period of time, as well as other known medical applications for NO. | 2011-10-06 |
20110244002 | MESOPOROUS MATERIAL EXCIPIENTS FOR POORLY AQUEOUS SOLUBLE INGREDIENTS - The present invention encompasses formulations and methods for producing solid dispersions comprising mesoporous materials with poorly aqueous soluble active ingredients. The active ingredient is formed in the amorphous state and entrapped in the nanosized pores of the mesoporous excipients using a co-spray drying process. The pore walls of mesoporous channels stabilize the amorphous form of active ingredient against re-crystallization. The amorphous active ingredient entrapped in mesoporous channels exhibits good stability during extended storage under stress test conditions and possesses significantly enhanced dissolution rates. | 2011-10-06 |
20110244003 | Self Standing Nanoparticle Networks/Scaffolds with Controllable Void Dimensions - The present invention discloses a self standing network or scaffold of nanoparticles with controllably variable mesh size between 500 nm and 1 mm having particle volume fraction between 0.5 to 50%. The network comprises nanoparticles, a surfactant capable of forming ordered structured phases and a cross linking agent, wherein the surfactant is washed off leaving the self standing scaffold. The invention further discloses the process for preparing the self standing scaffolds and uses thereof. | 2011-10-06 |
20110244004 | ANTIFUNGAL COMPOSITION WITH ENHANCED BIOAVAILABILITY - A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: | 2011-10-06 |
20110244005 | CONTROLLED RELEASE CGRP DELIVERY COMPOSITION FOR CARDIOVASCULAR AND RENAL INDICATIONS - The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies. | 2011-10-06 |
20110244006 | MICROSPHERE SKIN TREATMENT - This application provides a microsphere suitable for tissue engineering that comprises connective tissue growth factor (CTGF). Also provided is a matrix, material or scaffold suitable for tissue engineering that comprises connective tissue growth factor (CTGF) and basic fibroblast growth factor (bFGF). Additionally, methods of treating skin of a human are provided. The methods comprise administering to the skin microspheres comprising a growth factor that increases fibroblast proliferation or collagen, elastin, or glycosaminoglycan synthesis. Further provided are the use of the above microspheres for the treatment of the skin of a human. Additionally, this application proves the use of the above microsphere for the manufacture of a medicament for the treatment of the skin of a human. | 2011-10-06 |
20110244007 | SPHERICAL COMPOSITE PARTICLES AND METHOD FOR MANUFACTURING THE SAME - Disclosed are a method for manufacturing spherical composite particles, by which desired functions are simply and efficiently imparted to the surface or inside of the spherical composite particles; and spherical composite particles obtained by the method. | 2011-10-06 |
20110244008 | COSMETIC COMPOSITION - A cosmetic composition having an excellent ultraviolet and infrared protection function, a greatly improved feeling of use and high product stability such as color stability. | 2011-10-06 |
20110244009 | Children's Hygiene Products Shaped Like Sports Balls - A child's hygienic product comprises a body of hygiene material having an exterior surface simulating a sports ball that is sized to fit the palm of a child's hand. The hygiene material's body has a through hole communicating with the exterior surface at spatially separated regions. A portion of a generally looped shaped cord or band of resiliently stretchable material is positioned within the through-hole, and the portion emerging from the spatially separated regions extends around the outside surface of the hygiene material's body in close proximity thereto. The band is sized to extend around the hand of the child when the hygiene material's body is held by the child to generally secure the hygiene material's body in a position adjacent the child's palm when the child is using the product. | 2011-10-06 |
20110244010 | Medical devices including medicaments and methods of making and using same - The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition. | 2011-10-06 |
20110244011 | SPECIFIC DELIVERY OF AGROCHEMICALS - The present invention relates to specific delivery of agrochemicals to plants. More specifically, it relates to a composition, essentially consisting of a targeting agent comprising at least one binding domain that specifically binds to a binding site on an intact living plant and an agrochemical or a combination of agrochemicals. The present invention relates further to a binding domain that specifically binds the binding site on an intact living plant. More specifically, it relates to binding domains comprising an amino acid sequence that comprises four framework regions and three complementary determining regions, or any suitable fragment thereof, whereby the binding domains are capable to bind or retain a carrier onto a plant. In one preferred embodiment, the invention relates to binding domains which specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer. The invention relates further to a method for delivery of agrochemicals to a plant, for improving the deposition of agrochemicals on a plant, and for retaining the agrochemicals on a plant, using targeting agents comprising the binding domains, and to a method for protecting a plant against biotic or abiotic stress or controlling plant growth using the same. Also, the invention relates to a method for manufacturing a specifically targeting agrochemical carrier. | 2011-10-06 |
20110244012 | FUNGICIDE, PHOTO CATALYTIC COMPOSITE MATERIAL, ADSORBENT, AND DEPURATIVE - Disclosed herein is a fungicide, including: a porous carbon material; and a silver member adhered to the porous carbon material, wherein a value of a specific surface area based on a nitrogen BET, namely | 2011-10-06 |
20110244013 | MICROPOROUS MATERIAL FROM ETHYLENE-CHLOROTRIFLUOROETHYLENE COPOLYMER AND METHOD FOR MAKING SAME - Microporous material having a spherulitic matrix made from ethylene chlorotrifluoroethylene copolymer has a plurality of pores having an average pore size greater than about 0.01 micrometer. The material is made by thermally induced phase separation (TIPS) process that includes melt mixing ethylene chlorotrifluoroethylene copolymer, diluent and nucleating agent to provide a melt mixed composition; shaping the melt mixed composition; cooling the shaped melt mixed composition to induce phase separation of the ethylene chlorotrifluoroethylene copolymer to provide a phase separated material; and stretching the phase separated material to provide the microporous material. The microporous material may be incorporated into articles and the articles may include one, two or more layers of microporous material. | 2011-10-06 |
20110244014 | IMPLANTABLE MEDICAL ARTICLES HAVING LAMININ COATINGS AND METHODS OF USE - Laminin-containing coatings for the surfaces of implantable medical devices are disclosed. The coatings promote the formation of vessels in association with the coated surfaces with minimal fibrotic response. | 2011-10-06 |
20110244015 | IMPLANTABLE DEVICE FOR THE DELIVERY OF OCTREOTIDE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs. | 2011-10-06 |
20110244016 | MEDICAL IMPLANT HAVING A COATING COMPOSED OF OR CONTAINING AT LEAST ONE ACTIVE SUBSTANCE - One embodiment of the invention relates to a medical implant whose surface is completely or partially covered by a coating composed of at least one active substance or containing at least one active substance. | 2011-10-06 |
20110244017 | Absorbable Coating For Implantable Device - The present invention provides an absorbable coating for an implantable device and the methods of making and using the same. | 2011-10-06 |
20110244018 | DECONTAMINANT EDIBLE PRODUCT, METHODS OF PRODUCTION AND USES THEREOF - The invention relates to an edible product containing a decontaminant. Particularly, the invention relates to an edible product, for instance, a food-like product, containing an effective amount of activated charcoal to mitigate, substantially reduce or cause the cessation of at least one adverse effect associated with the ingestion of a toxic substance. The invention also relates to methods for manufacturing such a decontaminant edible product and uses thereof. | 2011-10-06 |
20110244019 | ABSORBENT FABRIC IMPLANT - Disclosed is a method and device for treating a tissue defect, disease or abnormality. The device includes an absorbent container adapted to be placed at a tissue site, the container constructed and arranged to absorb a bioactive solution prior to the placement at the tissue site and to carry the solution to the tissue site such that the solution interacts with the tissue and wherein the absorbent container is substantially free of a metal support structure. The method includes providing an absorbent container substantially free of a metal support structure, soaking the container in a bioactive solution such that the solution is absorbed by the container and placing the container at the tissue site such that the solution interacts with the tissue. | 2011-10-06 |
20110244020 | DRUG CONDENSATION AEROSOLS AND KITS - The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 μm, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits. | 2011-10-06 |
20110244021 | ANTIMICROBIAL AND IMMUNOSTIMULATING COMPOSITION - A medical composition comprising an antimicrobially effective and immunostimulating amount of a combination of a β-glucan component and a silver-containing component is disclosed. The medical composition may be adapted for use topically or incorporated with a mesh material which may be further adapted for use as a wound dressing or as a surgical mesh. Methods for manufacturing the medical compositions described herein are also provided. The invention further provides methods for treating tissue damaged by wound or burn, and methods for treating or repairing tissue at a surgical site. | 2011-10-06 |
20110244023 | TRANSDERMAL DELIVERY PATCH - A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier. | 2011-10-06 |
20110244024 | MICRORNA COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELOGENOUS LEUKEMIA - The invention provides methods, uses, kits and compositions comprising a therapeutically effective amount of the microRNA miR-223 for treating myelogenous leukemia in a subject in need of such treatment. The invention further comprises methods encompassing the use of miR-223 for promoting the differentiation of a leukemia stem cell that is resistant to a differentiating agent, and a method of screening for candidate compounds capable of treating a myeloid leukemia by comparison of the therapeutic activity of the candidate compound with the therapeutic activity of miR-233. | 2011-10-06 |
20110244025 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY - The invention provides immunostimulatory compositions and methods for their use. In particular, the immunostimulatory compositions of the invention include RNA-like polymers that incorporate an immunostimulatory sequence motif and at least one chemical modification to confer improved stability against nuclease degradation and improved activity. Specific modifications involving phosphate linkages, nucleotide analogs, and combinations thereof are provided. Compositions of the invention optionally include an antigen and can be used to stimulate an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an to allergic condition, or asthma. Modified oligoribonucleotide analogs of the invention are believed to stimulate Toll-like receptors TLR7 and TLR8. | 2011-10-06 |
20110244026 | DELIVERY OF MRNA FOR THE AUGMENTATION OF PROTEINS AND ENZYMES IN HUMAN GENETIC DISEASES - Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies. | 2011-10-06 |
20110244027 | 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections - The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses. | 2011-10-06 |
20110244028 | METHOD OF SOLUBILIZING BIOLOGICALLY ACTIVE COMPOUNDS - The invention describes a method of preparing lipid compositions by associating pH sensitive compounds which maybe weak acids, bases or amphoteric compounds with at least one ionisable or pH sensitive group and low water solubility into preformed and standardised lipid particles by pH manipulation. Drug association is carried out in situ by changing the pH of the aqueous medium to pH 6-8 wherein the compound spontaneously partitions into the lipid particles. Drug association may also be carried out by exploiting pH changes in the GI tract. The lipophilic compound is solubilised by the lipid particles and may be used as such for in-vitro and pharmacokinetic assessments or processed for oral, parenteral or topical therapy. | 2011-10-06 |
20110244029 | COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAME - The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes. The present disclosure also provides a method of removal of non-encapsulated active agent from the composition of matter, a method of preparing said composition of matter, a pharmaceutical composition comprising said composition of matter, use of such composition of matter; a method of providing prolonged delivery of a active agent to a subject in need thereof by administering to said subject the composition of matter disclosed herein as well as a package comprising said composition of matter held within said aqueus medium and instructions for use thereof. | 2011-10-06 |
20110244030 | TOPICAL FOAMING COMPOSITON AND METHOD OF APPLICATION - There is provided a topical foaming composition for the uniform distribution of formulations without drizzle formation. In accordance with the present invention, the topical composition contains a foaming agent and a pharmaceutically acceptable topical carrier. In accordance with the present invention, the composition may contain at least one active agent incorporated into the topical foaming composition. In accordance with a method of the present invention, the composition is capable of forming a stable foam in the present of a gas and the foam produced therefrom is topically applied on a subject in need thereof. | 2011-10-06 |
20110244031 | POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS - A tablet composition, which in an easy, flexible and reproducible manner can be loaded with a relatively high amount of a pharmaceutically acceptable oily substance, may be produced in large-scale batches and stored until use; and tablets loaded with a pharmaceutically acceptable oily substance as well as a method for the preparation thereof. The tablet composition comprises a release enhancing agent and provides high and/or consistent release of the pharmaceutically acceptable oily substance, in particular release of a pharmaceutically acceptable, but substantially water-insoluble, oily substance. | 2011-10-06 |
20110244032 | DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES - Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less. | 2011-10-06 |
20110244033 | TAMSULOSIN PELLETS FOR FIXED DOSE COMBINATION - The invention relates to a population of tamsulosin-comprising pellets for oral administration of a combination dosage form containing physically separated a tamsulosin dose in the form of the population of the tamsulosin comprising pellets and at least one other dose of a pharmaceutically active substance, said pellets comprising tamsulosin hydrochloride uniformly dispersed in a carrier matrix, wherein (i) said pellets in the population have a size of less than about 1.4 mm and, advantageously, at least 90% of the pellets have a size of larger than 0.30 mm; and (ii) an average content of tamsulosin hydrochloride in the population of pellets is between about 0.15-3.00 weight percent, calculated on a dry pellet basis, to a process of making such population of pellets, and to their use. | 2011-10-06 |
20110244034 | SUSTAINED RELEASE DRUG DELIVERY SYSTEM - The invention discloses a controlled release dosage form comprising a therapeutically effective amount of a pharmaceutically active agent, illustrated by Acyclovir, that would release in about 12 hours not more than about 90% of the said active agent in a simulated gastric juice in a first order rate of release in a USP type 1 dissolution test, and not containing a solubilizer or a swelling enhancer or both, comprising (a) a tablet made from polymer matrix of at least two biocompatible polymers, illustrated by Carbopol 974P and polyethylene oxide, the said pharmaceutically active agent and pharmaceutically permitted excipients; the said tablet capable of rapid swelling without disintegration in the said simulated gastric juice to a size that shall result in its gastric retention in the stomach and start controlled release of the said active agent by starting controlled erosion as well as diffusion immediately after coming into contact with the said gastric juice, or (b) microspheres of ungrafted chitosan or a chitosan derivative illustrated by thiolated chitosan and trimethyl chitosan, or Carbopol incorporating the said active agent, wherein the said pharmaceutically active agent is not a polymeric molecule and after administration in stomach, the said microspheres adhare to the gastric mucosa for a long time releasing the active agent in a controlled way. | 2011-10-06 |
20110244035 | Dosage Forms - Dosage forms comprising therapeutically active compounds are disclosed herein. | 2011-10-06 |
20110244036 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND - Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): | 2011-10-06 |
20110244037 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND - Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): | 2011-10-06 |
20110244038 | BERRY PREPARATIONS AND EXTRACTS - Compositions having antioxidant and anti-inflammatory activity, and methods for providing such compositions, are disclosed. In one aspect, the compositions are derived by exposing a berry to an acidic solvent composition, adding a cryoprotectant, and recovering a berry extract having a stabilized anthocyanin content. Compositions comprising the stabilized anthocyanin-containing berry extract, formulated for oral and/or topical administration, are provided also. | 2011-10-06 |
20110244039 | ABSORBABLE SOLID COMPOSITIONS FOR TOPICAL TREATMENT OF ORAL MUCOSAL DISORDERS - The invention provides a solid, self-bioadhesive composition for topical application that adheres to the oral mucosal tissue comprising a therapeutically effective amount of at least one herbal or homeopathic active agent; and a pharmaceutically acceptable solid bioadhesive carrier in an amount from about 40 to 99 percent based on the weight of the whole composition. | 2011-10-06 |
20110244040 | FILM-COATED SCORED TABLET - A film-coated scored tablet in which the forms of respective parts associated with a score line are optimized so as to more preferably divide the film along the score line is provided. | 2011-10-06 |
20110244041 | PLANT EXTRACT HYDROLYSATES AND ANTIBACTERIAL PRODUCT CONTAINING THE SAME - The invention relates to a hydrolyzate from at least one extract of at least one plant material selected from the group consisting of at least one genus: | 2011-10-06 |
20110244042 | STABILIZED FORMULATIONS OF CNS COMPOUNDS - Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone. | 2011-10-06 |
20110244043 | Controlled releasing composition - A controlled releasing composition comprising a plurality of microparticles and a matrix as well as the preparation method thereof is disclosed. The plurality of microparticles comprise a first material and the matrix comprises a second material. The melting temperature of the first material is higher than the melting temperature of the second material. | 2011-10-06 |
20110244044 | COMPOUND, MEDICAMENT, VACCINE COMPOSITION AND NANOCAPSULES - The present invention relates to a compound comprising a polyelectrolyte and, covalently linked thereto, an immunological adjuvant and/or cell targeting ligand, wherein the covalently linked entity can have both adjuvant and cell targeting characteristics. The compound is used in the preparation of hydrophilic vaccine nanoparticles, which preferably have an antigenic compound or therapeutic agent, or genetic information encoding such compounds or agents entrapped in their matrix, or covalently linked to their surfaces. Vaccine compositions comprising the particles of the invention are advantageous, because a strong and long-lasting immune response is obtained following administration of a single dose. In a preferred embodiment, the polyelectrolyte of the compound is an anionic polymer, and the particle comprises a matrix comprising chitosan. | 2011-10-06 |
20110244045 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION - The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof. | 2011-10-06 |
20110244046 | Charge Reversible Polymers - Described are charge reversible polymers, peptides and their resulting colloidal particles, comprising polymers and peptides having primary and secondary amines that are protected as easily hydrolysable amides. The amides are charge-reversible such that at neutral pH they are negatively charged but become positively charged at pH less than 6 and thus are relatively stable at neutral pH but quickly hydrolyze at pH below 6. Incorporating a drug in a micelle or a polymer comprised of the charge-reversible polymers or peptides provides a drug carrier for delivering the drug preferentially to the solid tumor or other targeted cells. | 2011-10-06 |
20110244047 | FILM-FORM PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a film-form preparation having a rapid dissolution profile in the mouth and sufficient film strength, and also having excellent appearance and feel. More specifically, the present invention provides a film-form preparation including: a water-soluble edible polymer; and water-insoluble drug particles, wherein an average particle size of the drug particles is 0.1 to 60 μm. | 2011-10-06 |
20110244048 | MULTIFUNCTIONAL SELF-ASSEMBLING POLYMERIC NANOSYSTEMS - Libraries of nanoparticles comprising therapeutic agents and/or imaging agents are disclosed, as well as methods of making, customizing, and using such libraries of nanoparticles. | 2011-10-06 |